Alfuzosin
Chemical compound alfa1-blocker / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Uroxatral?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Alfuzosin, sold under the brand name Uroxatral among others, is a medication of the α1 blocker class. It is used to treat benign prostatic hyperplasia (BPH).[1]
Quick Facts Clinical data, Pronunciation ...
Clinical data | |
---|---|
Pronunciation | /ælˈfjuːzoʊsɪn/ al-FEW-zoh-sin |
Trade names | Uroxatral, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a64002 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 49% |
Protein binding | 82–90% |
Metabolism | Liver (CYP3A4-mediated) |
Elimination half-life | 10 hours |
Excretion | Feces (69%) and Urine (24%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.108.671 |
Chemical and physical data | |
Formula | C19H27N5O4 |
Molar mass | 389.456 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Close
As an antagonist of the α1 adrenergic receptor, it works by relaxing the muscles in the prostate and bladder neck, making urination easier.
Alfuzosin was patented in 1978 and approved for medical use in 1988.[2] It was approved in the US for benign prostatic hyperplasia in 2003. In 2020, it was the 336th-most commonly prescribed medication in the United States, with more than 700 thousand prescriptions.[3][4]